Table 2.
Antihypertensive and anti-anginal use before and during the study by treatment arm
| Amlodipine (n = 103) |
Atorvastatin (n = 104) |
Amlodipine + atorvastatin (n = 104) |
||||
|---|---|---|---|---|---|---|
| Before | During | Before | During | Before | During | |
| β-Blockers, n (%) | 79 (76.7) | 79 (76.7) | 89 (85.6) | 89 (85.6) | 83 (79.8) | 83 (79.8) |
| ACE-inhibitors, n (%) | 57 (55.3) | 57 (55.3) | 64 (61.5) | 65 (62.5) | 55 (52.9) | 55 (52.9) |
| Diuretics, n (%) | 17 (16.5) | 17 (16.5) | 25 (24.0) | 27 (26.0) | 21 (20.2) | 22 (21.2) |
| ARBs, n (%) | 2 (1.9) | 2 (1.9) | 4 (3.9) | 4 (3.9) | 3 (2.9) | 3 (2.9) |
| Other antihypertensive combinations, n (%) | 9 (8.7) | 4 (3.9) | 12 (11.5) | 7 (6.7) | 14 (13.5) | 8 (7.7) |
| Anti-anginal therapy, n (%) | 67 (65.0) | 67 (65.0) | 74 (71.2) | 74 (71.2) | 62 (59.6) | 60 (57.7) |
ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.